Editas Common Stock vs Current Deferred Revenue Analysis

EDIT Stock

USD 5.48 0.16 3.01%

Editas Medicine financial indicator trend analysis is much more than just examining Editas Medicine latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Editas Medicine is a good investment. Please check the relationship between Editas Medicine Common Stock and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Common Stock vs Current Deferred Revenue

Common Stock vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Editas Medicine Common Stock account and Current Deferred Revenue. At this time, the significance of the direction appears to have very week relationship.

The correlation between Editas Medicine's Common Stock and Current Deferred Revenue is 0.26. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Editas Medicine, assuming nothing else is changed. The correlation between historical values of Editas Medicine's Common Stock and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Editas Medicine are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Common Stock i.e., Editas Medicine's Common Stock and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.26

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Common Stock

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Editas Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.Enterprise Value is likely to gain to about 921.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	218.7M	245.7M	241.2M	167.7M
Cost Of Revenue	5.1M	6.3M	6.1M	5.8M

Total Operating Expenses Cost Of Revenue

Editas Medicine fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt
Total Assets		0.11	0.74	0.94	0.95	0.81	0.91	-0.81	-0.83	0.86	0.84	0.88	0.81	0.82	0.99	0.95	0.58	0.87	0.88	0.75	0.89	0.99	0.61	0.95	0.66	0.85
Short Long Term Debt Total	0.11		0.06	0.02	-0.13	0.09	0.02	0.22	-0.05	0.05	0.38	0.0	0.19	0.18	0.12	0.28	0.73	-0.03	-0.01	0.61	0.02	0.15	0.01	-0.11	-0.08	0.5
Other Current Liab	0.74	0.06		0.79	0.71	0.57	0.64	-0.45	-0.92	0.75	0.49	0.77	0.55	0.84	0.69	0.78	0.39	0.81	0.9	0.54	0.72	0.69	0.2	0.73	0.28	0.54
Total Current Liabilities	0.94	0.02	0.79		0.89	0.81	0.94	-0.82	-0.86	0.95	0.8	0.85	0.67	0.76	0.9	0.93	0.52	0.87	0.88	0.71	0.93	0.92	0.64	0.91	0.72	0.82
Total Stockholder Equity	0.95	-0.13	0.71	0.89		0.66	0.88	-0.81	-0.83	0.82	0.69	0.93	0.82	0.83	0.94	0.87	0.31	0.87	0.88	0.51	0.88	0.91	0.5	1.0	0.59	0.68
Other Liab	0.81	0.09	0.57	0.81	0.66		0.74	-0.77	-0.56	0.68	0.78	0.47	0.42	0.41	0.81	0.71	0.73	0.65	0.6	0.83	0.62	0.88	0.78	0.66	0.74	0.73
Property Plant And Equipment Net	0.91	0.02	0.64	0.94	0.88	0.74		-0.84	-0.81	0.94	0.81	0.81	0.72	0.72	0.88	0.9	0.47	0.73	0.84	0.66	0.97	0.89	0.75	0.88	0.74	0.84
Net Debt	-0.81	0.22	-0.45	-0.82	-0.81	-0.77	-0.84		0.57	-0.7	-0.81	-0.6	-0.44	-0.49	-0.82	-0.68	-0.35	-0.62	-0.65	-0.52	-0.74	-0.84	-0.81	-0.8	-0.87	-0.66
Retained Earnings	-0.83	-0.05	-0.92	-0.86	-0.83	-0.56	-0.81	0.57		-0.87	-0.59	-0.88	-0.75	-0.93	-0.77	-0.88	-0.36	-0.81	-0.99	-0.54	-0.89	-0.77	-0.36	-0.85	-0.41	-0.67
Accounts Payable	0.86	0.05	0.75	0.95	0.82	0.68	0.94	-0.7	-0.87		0.7	0.85	0.72	0.76	0.81	0.92	0.46	0.81	0.87	0.64	0.95	0.82	0.57	0.85	0.61	0.78
Cash	0.84	0.38	0.49	0.8	0.69	0.78	0.81	-0.81	-0.59	0.7		0.57	0.53	0.59	0.85	0.81	0.77	0.57	0.63	0.86	0.72	0.89	0.77	0.69	0.78	0.92
Non Current Assets Total	0.88	0.0	0.77	0.85	0.93	0.47	0.81	-0.6	-0.88	0.85	0.57		0.86	0.91	0.84	0.89	0.26	0.91	0.9	0.45	0.88	0.78	0.27	0.94	0.42	0.66
Non Currrent Assets Other	0.81	0.19	0.55	0.67	0.82	0.42	0.72	-0.44	-0.75	0.72	0.53	0.86		0.83	0.79	0.83	0.36	0.71	0.78	0.49	0.77	0.74	0.29	0.82	0.3	0.68
Other Assets	0.82	0.18	0.84	0.76	0.83	0.41	0.72	-0.49	-0.93	0.76	0.59	0.91	0.83		0.78	0.87	0.35	0.8	0.94	0.51	0.8	0.74	0.22	0.85	0.33	0.67
Cash And Short Term Investments	0.99	0.12	0.69	0.9	0.94	0.81	0.88	-0.82	-0.77	0.81	0.85	0.84	0.79	0.78		0.91	0.6	0.84	0.83	0.75	0.83	0.99	0.6	0.93	0.67	0.82
Common Stock Shares Outstanding	0.95	0.28	0.78	0.93	0.87	0.71	0.9	-0.68	-0.88	0.92	0.81	0.89	0.83	0.87	0.91		0.62	0.83	0.89	0.78	0.92	0.91	0.54	0.89	0.55	0.89
Non Current Liabilities Total	0.58	0.73	0.39	0.52	0.31	0.73	0.47	-0.35	-0.36	0.46	0.77	0.26	0.36	0.35	0.6	0.62		0.36	0.35	0.97	0.38	0.66	0.54	0.32	0.45	0.8
Other Current Assets	0.87	-0.03	0.81	0.87	0.87	0.65	0.73	-0.62	-0.81	0.81	0.57	0.91	0.71	0.8	0.84	0.83	0.36		0.84	0.55	0.75	0.8	0.26	0.88	0.5	0.6
Other Stockholder Equity	0.88	-0.01	0.9	0.88	0.88	0.6	0.84	-0.65	-0.99	0.87	0.63	0.9	0.78	0.94	0.83	0.89	0.35	0.84		0.54	0.89	0.82	0.41	0.9	0.48	0.68
Total Liab	0.75	0.61	0.54	0.71	0.51	0.83	0.66	-0.52	-0.54	0.64	0.86	0.45	0.49	0.51	0.75	0.78	0.97	0.55	0.54		0.58	0.81	0.63	0.52	0.57	0.89
Property Plant And Equipment Gross	0.89	0.02	0.72	0.93	0.88	0.62	0.97	-0.74	-0.89	0.95	0.72	0.88	0.77	0.8	0.83	0.92	0.38	0.75	0.89	0.58		0.84	0.59	0.9	0.58	0.79
Total Current Assets	0.99	0.15	0.69	0.92	0.91	0.88	0.89	-0.84	-0.77	0.82	0.89	0.78	0.74	0.74	0.99	0.91	0.66	0.8	0.82	0.81	0.84		0.69	0.9	0.71	0.86
Property Plant Equipment	0.61	0.01	0.2	0.64	0.5	0.78	0.75	-0.81	-0.36	0.57	0.77	0.27	0.29	0.22	0.6	0.54	0.54	0.26	0.41	0.63	0.59	0.69		0.5	0.86	0.72
Net Tangible Assets	0.95	-0.11	0.73	0.91	1.0	0.66	0.88	-0.8	-0.85	0.85	0.69	0.94	0.82	0.85	0.93	0.89	0.32	0.88	0.9	0.52	0.9	0.9	0.5		0.59	0.7
Current Deferred Revenue	0.66	-0.08	0.28	0.72	0.59	0.74	0.74	-0.87	-0.41	0.61	0.78	0.42	0.3	0.33	0.67	0.55	0.45	0.5	0.48	0.57	0.58	0.71	0.86	0.59		0.68
Long Term Debt	0.85	0.5	0.54	0.82	0.68	0.73	0.84	-0.66	-0.67	0.78	0.92	0.66	0.68	0.67	0.82	0.89	0.8	0.6	0.68	0.89	0.79	0.86	0.72	0.7	0.68

Click cells to compare fundamentals

Editas Medicine Account Relationship Matchups

Editas Medicine fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	508.9M	572.6M	677.5M	514.3M	499.2M	395.9M
Short Long Term Debt Total	29.1M	26.1M	26.4M	43.9M	36.5M	33.9M
Other Current Liab	24.8M	24.0M	20.2M	31.3M	34.6M	36.3M
Total Current Liabilities	60.0M	58.2M	46.9M	60.1M	63.2M	40.9M
Total Stockholder Equity	262.4M	393.6M	553.6M	360.7M	349.1M	239.8M
Other Liab	163.2M	101.5M	60.9M	60.7M	69.8M	71.4M
Property Plant And Equipment Net	39.6M	39.1M	43.3M	59.2M	45.7M	35.0M
Net Debt	(209.1M)	(113.5M)	(177.1M)	(97.6M)	(87.1M)	(91.5M)
Retained Earnings	(549.2M)	(665.2M)	(857.7M)	(1.1B)	(1.2B)	(1.2B)
Accounts Payable	5.8M	6.4M	5.1M	9.5M	8.3M	5.3M
Cash	238.2M	139.7M	203.5M	141.5M	123.7M	146.9M
Non Current Assets Total	45.0M	153.5M	170.2M	157.6M	158.3M	82.0M
Non Currrent Assets Other	107K	4.7M	6.8M	5.3M	4.7M	3.3M
Other Assets	1.7M	4.7M	6.8M	5.3M	6.0M	6.3M
Cash And Short Term Investments	457.1M	511.8M	619.9M	437.4M	323.1M	338.9M
Common Stock Shares Outstanding	50.0M	58.6M	67.6M	68.7M	76.0M	49.3M
Liabilities And Stockholders Equity	508.9M	572.6M	677.5M	514.3M	499.2M	395.9M
Non Current Liabilities Total	186.5M	120.8M	77.0M	93.5M	86.8M	115.2M
Other Current Assets	6.3M	10.9M	7.2M	7.3M	7.5M	4.3M
Other Stockholder Equity	811.5M	1.1B	1.4B	1.4B	1.6B	1.7B
Total Liab	246.4M	179.0M	123.8M	153.6M	150.1M	156.1M
Property Plant And Equipment Gross	39.6M	39.1M	58.8M	80.7M	72.0M	41.4M
Total Current Assets	463.8M	419.1M	507.3M	356.8M	340.8M	314.0M
Accumulated Other Comprehensive Income	107K	(46K)	(493K)	(3.6M)	198K	207.9K
Property Plant Equipment	39.6M	14.0M	17.1M	15.6M	17.9M	23.1M
Net Tangible Assets	262.4M	393.6M	553.6M	360.7M	414.8M	250.7M
Current Deferred Revenue	23.5M	20.9M	11.3M	8.2M	9.5M	14.2M
Net Receivables	418K	6.0M	267K	5.1M	10.2M	10.7M
Short Term Debt	5.8M	6.8M	10.3M	11.1M	12.2M	9.5M
Short Term Investments	219.0M	262.4M	296.3M	202.8M	199.5M	195.2M
Capital Surpluse	811.5M	1.1B	1.4B	1.4B	1.7B	854.8M
Retained Earnings Total Equity	(549.2M)	(665.2M)	(857.7M)	(1.1B)	(970.3M)	(921.8M)
Capital Lease Obligations	29.1M	26.1M	26.4M	43.9M	36.5M	36.2M

Editas Medicine Investors Sentiment

The influence of Editas Medicine's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Editas. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Editas Medicine's public news can be used to forecast risks associated with an investment in Editas. The trend in average sentiment can be used to explain how an investor holding Editas can time the market purely based on public headlines and social activities around Editas Medicine. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Editas Medicine's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Editas Medicine's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Editas Medicine's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Editas Medicine.

Editas Medicine Implied Volatility

206.91

Editas Medicine's implied volatility exposes the market's sentiment of Editas Medicine stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Editas Medicine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Editas Medicine stock will not fluctuate a lot when Editas Medicine's options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Editas Medicine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Editas Medicine's short interest history, or implied volatility extrapolated from Editas Medicine options trading.

Pair Trading with Editas Medicine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.

Moving together with Editas Stock

0.61	DVAX	Dynavax Technologies Financial Report 7th of May 2024	Pair Corr
0.83	EGRX	Eagle Pharmaceuticals	Pair Corr
0.77	ELAN	Elanco Animal Health Financial Report 14th of May 2024	Pair Corr

Moving against Editas Stock

0.81	ACB	Aurora Cannabis Sell-off Trend	Pair Corr
0.72	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr
0.47	FLGC	Flora Growth Corp Financial Report 20th of May 2024	Pair Corr

The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.

The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Editas Medicine is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Editas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Editas Medicine Stock. Highlighted below are key reports to facilitate an investment decision about Editas Medicine Stock:

How To Invest In Editas

Details

Is Editas Stock a good investment?

Details

What is Editas Medicine's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Editas Stock analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Fundamental Analysis View fundamental data based on most recent published financial statements

Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.02)

Revenue Per Share

1.028

Quarterly Revenue Growth

8.187

Return On Assets

(0.21)

Return On Equity

(0.43)

The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Editas Common Stock vs Current Deferred Revenue Analysis

Common Stock vs Current Deferred Revenue

Common Stock vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Common Stock

Current Deferred Revenue

Editas Medicine fundamental ratios Correlations

Editas Medicine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Editas Medicine fundamental ratios Accounts

Editas Medicine Investors Sentiment

Editas Medicine Implied Volatility

Pair Trading with Editas Medicine

Moving together with Editas Stock

Moving against Editas Stock

Complementary Tools for Editas Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net
Total Liab	+ 0.97	Non Current Liabilities Total

Other Stockholder Equity	- 0.99	Retained Earnings
Other Assets	- 0.93	Retained Earnings
Retained Earnings	- 0.92	Other Current Liab
Property Plant And Equipment Gross	- 0.89	Retained Earnings
Common Stock Shares Outstanding	- 0.88	Retained Earnings
Non Current Assets Total	- 0.88	Retained Earnings